Type-II Interferon (IFNγ) Engineering Services
Creative Biolabs specializes in the rational design and production of IFNγ variants, engineered for precise control over the JAK/STAT signaling cascade. Our core capability is developing molecules that manage IFNγ's duality, delivering targeted efficacy for distinct therapeutic needs. We aim to maximize desirable immune responses (e.g., anti-tumor, anti-fibrotic) while minimizing unwanted inflammatory or immunosuppressive effects. This approach leverages our deep understanding of IFNγ biology to create superior, safer, and more effective biotherapeutics, moving beyond the limitations of native IFNγ for a range of therapeutic applications.
Background Featured Services Workflow Why Choose Us FAQs Customer Review Related Services Contact Us
The Therapeutic Duality of IFNγ: Agonism vs. Antagonism
IFNγ is the primary type-II interferon secreted primarily by NK cells and T lymphocytes, making it crucial for coordinating both adaptive and innate immunity. While IFNγ is vital for clearing intracellular pathogens and surveilling tumors, its chronic and uncontrolled activation is the root cause of significant pathological processes. Recent immunological literature confirms its role in driving MHC II-mediated autoimmunity and chronic inflammation (e.g., in arthritis) through the sustained induction of the CIITA transactivator. Therefore, precise control over IFNγ signaling—whether boosting its anti-tumor effects (agonism) or blocking its inflammatory effects (antagonism)—is essential for the next generation of therapeutics. This therapeutic duality mandates sophisticated protein engineering to maximize therapeutic benefits while mitigating harmful systemic and inflammatory effects.
Fig.1 The dual role of IFN-γ on malignant and immune cells. 1
Our Featured Services
Targeted IFNγ Delivery Engineering
Creative Biolabs' targeted IFNγ delivery engineering service develops next-generation molecules to precisely control IFNγ's potent duality, maximizing anti-tumor/anti-pathogen effects while minimizing systemic toxicity and autoimmunity.
Learn More →
Contact our expert team today for a confidential consultation and a tailored project proposal.
Workflow: IFNγ Engineering from Design to Deliverable
The typical workflow for our IFNγ engineering services is a rigorous, five-phased approach designed for maximum clarity, control, and iterative success, allowing for seamless integration into your preclinical development pipeline.
Why Choose Us?
Our commitment to structure-guided design and specialization in cytokine biology positions Creative Biolabs as the industry leader for IFNγ therapeutics development. We move beyond generic protein expression to deliver molecules with defined signaling properties and improved clinical profiles.
-
Targeted Signal Decoupling
Utilizing the latest structural data on the hexameric receptor complex for the rational design of both biased agonists (for oncology) and highly potent antagonists (for autoimmunity).
-
20+ Years of Cytokine Expertise
Deep institutional knowledge of the complex regulatory and JAK/STAT signaling pathways of IFNγ ensures successful design from conception to validation.
-
Specialized Functional QC Assays
Implementation of proprietary assays, including the MHC II suppression assay and biased agonism assay, provides robust, biologically relevant functional proof-of-concept.
-
High-Quality Mammalian Expression
Guaranteed correct folding and glycosylation patterns are essential for the in vivo stability and biological function of IFNγ variants.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q1: My project requires an IFNγ that only activates anti-tumor genes, but not immunosuppressive ones like PD-L1. Can Creative Biolabs' service achieve this decoupling?
A1: Yes, absolutely. We use structure-guided design to engineer variants that preferentially trigger the signal transducer associated with anti-tumor immunity (MHC I induction) while actively downregulating those that cause resistance (PD-L1).
Q2: What is the main advantage of using an engineered IFNγ cytokine variant over a standard monoclonal neutralizing antibody?
A2: Engineered antagonists can be designed to be smaller or more stable, potentially leading to better tissue penetration and faster, more controllable clearance, which is critical for safety.
Q3: The native IFNγ has a very short serum half-life. Does Creative Biolabs offer services to improve the pharmacokinetics (PK) of my lead candidate?
A3: Yes. We utilize advanced strategies such as site-specific PEGylation or fusion to Fc domain fragments to significantly increase the molecule's half-life. Our design process ensures these modifications do not interfere with the primary receptor binding or signaling mechanism.
Customer Reviews
-
Decoupled Signaling
The biased agonist variant was critical for avoiding dose-limiting PD-L1 upregulation in the tumor microenvironment, making our combination with a PD-1 inhibitor highly synergistic without the usual resistance issues. The specialized bias ratio data was invaluable. – Dr. Al***rt
-
PK Improvement
The PK-enhanced IFNγ antagonist, designed with albumin fusion, reduced our required injection frequency in the animal model from daily to weekly, drastically improving experimental throughput and reducing costs. - Prof. J***na
Related Services
To fully realize the potential of your IFNγ project, Creative Biolabs recommends leveraging our comprehensive suite of complementary services designed to accelerate your preclinical pipeline.
Cell Culture Process Development Services
Creative Biolabs develops high-productivity mammalian/microbial cell lines for immunotherapy, optimizing clone selection and cell culture conditions to meet product quality targets and scalable manufacturing needs.
Learn More →
Monocyte Activation Test
Creative Biolabs' monocyte activation test (MAT) is an in vitro assay using human blood to detect pyrogens in parenteral drugs and biologics, offering a sensitive, reliable alternative to RPT and LAL tests for problematic products.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs offers complete IFNγ engineering solutions, from structure-guided design of biased agonists for oncology to potent antagonists for autoimmune and inflammatory diseases. Our commitment to quality, backed by two decades of expertise and specialized functional assays, ensures your therapeutic candidates are optimized for maximum efficacy and clinical viability.
Contact Our Team for More Information and to Discuss Your Project Scope Today
Reference
-
Fenton, Sarah E., Diana Saleiro, and Leonidas C. Platanias. "Type I and II Interferons in the Anti-Tumor Immune Response." Cancers 13.5 (2021): 1037. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers13051037
